Adderall

GPTKB entity

Statements (67)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Shire_plc
gptkb:Quillivant_XR
gptkb:Concerta
gptkb:Shire_Pharmaceuticals
gptkbp:appointed_by oral route
gptkbp:approves gptkb:1996
gptkbp:can_lead_to mood swings
gptkbp:caused_by gptkb:software
dizziness
fatigue
withdrawal symptoms
nervousness
stomach pain
headaches
gptkbp:contains gptkb:amphetamine
gptkb:dextroamphetamine
gptkbp:enhances cognitive performance
gptkbp:formulation extended-release
immediate-release
https://www.w3.org/2000/01/rdf-schema#label Adderall
gptkbp:increased blood pressure
gptkbp:ingredients psychiatrists
primary care physicians
C9 H13 N
gptkbp:interacts_with antidepressants
MAO inhibitors
blood pressure medications
gptkbp:is_associated_with euphoria
improved focus
increased energy
potential for abuse
gptkbp:is_atype_of N06 B A03
gptkbp:is_available_in various strengths
gptkbp:is_available_on oral tablet
extended-release capsule
gptkbp:is_considered a Schedule II drug
effective for many patients
gptkbp:is_often_associated_with gptkb:psychologist
gptkbp:is_often_used_in to enhance academic performance
for recreational purposes
to lose weight
gptkbp:is_part_of comprehensive treatment plan
treatment regimen for ADHD
gptkbp:is_subject_to regulatory scrutiny
drug testing
gptkbp:is_used_by gptkb:Person
adults
gptkbp:is_used_for treatment of ADHD
treatment of narcolepsy
gptkbp:legal_issue controlled substance
gptkbp:manufacturer gptkb:Shire_Pharmaceuticals
gptkbp:marketed_as various brand names
gptkbp:requires gptkb:theorem
gptkbp:side_effect anxiety
insomnia
dry mouth
increased heart rate
loss of appetite
gptkbp:suitable_for pregnant women
nursing mothers
patients with glaucoma
patients with hyperthyroidism
patients with a history of substance abuse
patients with heart problems
gptkbp:type_of 300-62-9